Table 1.

Demographic data of the patients at the point of study inclusion.

	Total	Active Group	Non Active Group	p Value
N	92	40	52
Age, mean ± SD, years old	37.2 ± 12.3	37.5 ± 12.3	37.1 ± 12.9	0.8624
Gender, M/F	68/24	29/11	39/13	0.9751
BMI	21.3 ± 3.2	21.5 ± 3.6	21.1 ± 2.9	0.603
Duration of disease, mean ± SD, months	117.1 ± 96.7	93.9 ± 73.3	135 ± 108.8	0.093
Montreal classification
Age at diagnosis
<17 years	7	3	4
17–40 years	70	30	40
>40 years	15	7	8
Location
L1—ileal	38	17	21
L2—colonic	0
L3—ileocolonic	54	23	31
Behavior
B1—Non-stricturing, non-penetrating	72	28	44
B2—Stricturing	15	9	6
B3—Penetrating	5	3	2
p-perianal disease	9	6	3
History of GI surgery	53/92	25/40	28/52	0.5353
Ileo-colonic resection	26	12	14
Ileal resection	21	9	12
Ileo-colonic resection plus Ileal resection	4	3	1
Colonic resection	2	1	1
Any symptom	28/92	19/40	9/52	0.0038
CDAI	104 ± 56	116 ± 72	95 ± 39	0.277
Laboratory data
CRP (mg/dL), mean ± SD	0.36 ± 0.62	0.53 ± 0.75	0.24 ± 0.47	0.0761
Hb (g/dL), mean ± SD	13.3 ± 2.1	12.7 ± 2.5	13.8 ± 1.6	0.0201
Albumin (g/dL), mean ± SD	4.0 ± 0.5	3.9 ± 0.5	4.2 ± 0.4	0.0014
Indication of CE
Symptom(s)	28	19	9
diarrhea	20	15	5
abdominal pain	4	2	2
bloody stools	3	2	1
abdominal fullness	1	0	1
Monitoring	64	21	43
PPC and CE
PPC intact body excretion	62/92	26/40	36/52	0.8377
Gastric transit time (min.)	45.5 ± 42.4	45.6 ± 40.3	47.2 ± 44.3	0.9904
SBTT (min.)	248.8 ± 128.8	270.7 ± 149.5	231.7 ± 108.5	0.3042
Lewis score, mean ± SD	396 ± 706	844 ± 892	52.1 ± 66.1	<0.0001
Treatment
Anti TNF-α agent	54/92	23/40	31/52
5-ASA	78/92	35/40	43/52
Immunomodulator	14/92	5/40	9/52
Elemental diet	57/92	23/40	34/52